The quest for the development of bone substitutes with contrast agents for diagnostic imaging subsists to distinguish synthetic bone from native human tissue. To this aim, ytterbium (Yb) substitutions in β-tricalcium phosphate (β-Ca(PO), β-TCP) as contrast agents has been developed to differentiate implant materials thereby, facilitating as host for bimodal imaging application by means of NIR luminescence and X-ray computed tomography techniques. A facile aqueous chemical precipitation route with the aid of surfactant is used for the synthesis of Yb substitutions in β-Ca(PO). The characterization results affirms the ability of β-Ca(PO) to host 4.36 mol% of Yb while the excess Yb crystallizes as YbPO. The structure refinement results favour the occupancy of Yb at the Ca(5) site of β-Ca(PO). The absorption and photoluminescence spectra in the near infrared region with emission intensity ~1024 nm in the second biological window correspond to F → F transitions of Yb. The designed Yb substituted β-Ca(PO) does not exhibit any toxicity in human osteosarcoma cell lines and delivers an excellent in vitro CT contrast ability allied by the enhanced signal intensity and high X-ray absorption coefficient.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.msec.2018.06.032 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!